

# CITATION REPORT

List of articles citing

## Role of Androgen Receptor in Prostate Cancer: A Review

DOI: 10.5534/wjmh.180040

World Journal of Men's Health, 2019, 37, 288-295.

**Source:** <https://exaly.com/paper-pdf/72640087/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
214	The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer. <b>2019</b> , 11,		21
213	Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor. <b>2019</b> , 123, 7657-7666		16
212	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. <b>2019</b> , 6,		35
211	Clinical significance of serum PSA in breast cancer patients. <b>2019</b> , 19, 1021		3
210	Prognostic markers in salivary gland cancer and their impact on survival. <b>2019</b> , 41, 3338-3347		9
209	STAT3 Post-Translational Modifications Drive Cellular Signaling Pathways in Prostate Cancer Cells. <b>2019</b> , 20,		13
208	Steroid Receptor Signallings as Targets for Resveratrol Actions in Breast and Prostate Cancer. <b>2019</b> , 20,		17
207	Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells. <b>2019</b> , 33, e22338		2
206	Hits Discovery on the Androgen Receptor: In Silico Approaches to Identify Agonist Compounds. <b>2019</b> , 8,		1
205	hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen. <b>2019</b> , 9, 19076		9
204	Inhibition of Proliferation of Prostate Cancer Cell Line DU-145 in vitro and in vivo Using Salvia miltiorrhiza Bunge. <b>2020</b> , 26, 533-538		5
203	The Effect of Zinc, Selenium, and Their Combined Supplementation on Androgen Receptor Protein Expression in the Prostate Lobes and Serum Steroid Hormone Concentrations of Wistar Rats. <b>2020</b> , 12,		4
202	MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR. <b>2020</b> , 21, 34-42		11
201	Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel. <b>2020</b> , 80, 247-255		6
200	Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. <b>2020</b> , 15, 709-722		9
199	Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer. <b>2020</b> , 12,		11
198	Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets. <b>2020</b> , 15, e0237442		3

197	Protein Expression Analysis of an In Vitro Murine Model of Prostate Cancer Progression: Towards Identification of High-Potential Therapeutic Targets. <b>2020</b> , 10,	3
196	Roles of Reactive Oxygen Species in Biological Behaviors of Prostate Cancer. <b>2020</b> , 2020, 1269624	9
195	Metastatic colon cancer of the small intestine diagnosed using genetic analysis: a case report. <b>2020</b> , 15, 106	0
194	Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy. <b>2020</b> , 10, 1510	25
193	Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data. <b>2020</b> , 11,	1
192	Involvement of the MEN1 Gene in Hormone-Related Cancers: Clues from Molecular Studies, Mouse Models, and Patient Investigations. <b>2020</b> , 1, 58-81	1
191	Signaling through estrogen receptors modulates long non-coding RNAs in prostate cancer. <b>2020</b> , 511, 110864	5
190	Role of radical quenching activity of dihydrocanaric acid in the treatment of cancer-experimental and theoretical. <b>2020</b> , 10, 251	1
189	Urupocidin C: a new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting. <b>2020</b> , 10, 9764	9
188	Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. <b>2020</b> , 111, 1692-1698	7
187	Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy. <b>2020</b> , 12, 1756287220929481	2
186	One-Year, Open-Label Extension Study on the Safety and Efficacy of Abiraterone Acetate Fine Particle Formulation in Patients With Metastatic Castration-Resistant Prostate Cancer. <b>2020</b> , 13, 117956112091012	2
185	Challenges and Opportunities in Cancer Drug Resistance. <b>2021</b> , 121, 3297-3351	66
184	TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. <b>2021</b> , 81, 109-117	0
183	Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis. <b>2021</b> , 40, 465-474	13
182	Epigenetic modification-dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells. <b>2021</b> , 112, 691-702	2
181	Targeting the BAF complex in advanced prostate cancer. <b>2021</b> , 16, 173-181	2
180	Oxidative Stress, Diet and Prostate Cancer. <i>World Journal of Men's Health</i> , <b>2021</b> , 39, 195-207	6.8 14

179	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. <b>2021</b> , 13, 17562872211046794		
178	Circular RNAs: new biomarkers of chemoresistance in cancer. <b>2021</b> ,		5
177	Genomic Profiling of Prostate Cancer: An Updated Review. <i>World Journal of Men's Health</i> , <b>2021</b> ,	6.8	4
176	Introductory words. <b>2021</b> , 1-12		
175	Prostate Carcinogenesis: Insights in Relation to Epigenetics and Inflammation. <b>2021</b> , 21, 253-267		6
174	Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. <b>2021</b> , 131,		9
173	Targeting Mitochondrial Metabolism in Prostate Cancer with Triterpenoids. <b>2021</b> , 22,		7
172	Signaling Pathways That Control Apoptosis in Prostate Cancer. <b>2021</b> , 13,		2
171	Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer. <b>2021</b> , 22,		7
170	Pro-autoimmune allele of tyrosine phosphatase, PTPN22, enhances tumor immunity.		1
169	Improving Strategies in the Development of Protein-Downregulation-Based Antiandrogens. <b>2021</b> , 16, 2021-2033		2
168	NF- $\kappa$ B Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. <b>2021</b> , 19, 1137-1145		1
167	Proteogenomic Workflow Reveals Molecular Phenotypes Related to Breast Cancer Mammographic Appearance. <b>2021</b> , 20, 2983-3001		1
166	SRC-3, a Steroid Receptor Coactivator: Implication in Cancer. <b>2021</b> , 22,		2
165	The Influence of Anti-Diabetic Drugs on Prostate Cancer. <b>2021</b> , 13,		4
164	Steroidogenic cytochrome P450 17A1 structure and function. <b>2021</b> , 528, 111261		8
163	Targeting CDK9 for Anti-Cancer Therapeutics. <b>2021</b> , 13,		8
162	Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review. <b>2021</b> , 22,		1

161	Targeted nanomedicine modalities for prostate cancer treatment. <b>2021</b> , 56, 100762	7
160	Treatment and trials in non-metastatic castration-resistant prostate cancer. <b>2021</b> , 18, 433-442	5
159	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. <b>2021</b> , 96-97, 101-111	2
158	Detection of N,N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients. <b>2021</b> , 39, 116156	5
157	Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer. <b>2021</b> , 12, 1245-1252	
156	Mechanistic Insights into the Allosteric Inhibition of Androgen Receptors by Binding Function 3 Antagonists from an Integrated Molecular Modeling Study. <b>2021</b> , 61, 3477-3494	1
155	Implication of $\alpha$ -adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells. <b>2021</b> , 16, e0253828	
154	Signalling transduction of O-GlcNAcylation and PI3K/AKT/mTOR-axis in prostate cancer. <b>2021</b> , 1867, 166129	3
153	Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide. <b>2021</b> , 74, 706-716	
152	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. <b>2021</b> , 11,	3
151	SHH-N non-canonically sustains androgen receptor activity in androgen-independent prostate cancer cells. <b>2021</b> , 11, 14880	1
150	Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection. <b>2021</b> , 53, 2027-2039	2
149	Differential Expression of the Androgen Receptor, Splice Variants and Relaxin 2 in Renal Cancer. <b>2021</b> , 11,	0
148	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. <b>2021</b> , 22,	4
147	Novel Prostate Cancer Biomarkers: Aetiology, Clinical Performance and Sensing Applications. <b>2021</b> , 9, 205	4
146	miR-28-3p inhibits prostate cancer cell proliferation, migration and invasion, and promotes apoptosis by targeting ARF6. <b>2021</b> , 22, 1205	1
145	An update of new small-molecule anticancer drugs approved from 2015 to 2020. <b>2021</b> , 220, 113473	11
144	Phytoestrogens as Potential Antiandrogenic Agents against Prostate Cancer: An In Silico Analysis. <b>2021</b> , 18,	0

143	Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity. <b>2021</b> , 207, 1662-1671	2
142	A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response. <b>2021</b> , 11,	1
141	Peptide based nano-drug candidate for cancer treatment: Preparation, characterization, in vitro and in silico evaluation. <b>2021</b> , 1240, 130573	2
140	LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance. <b>2021</b> , 12, 856	3
139	Phasing the intranuclear organization of steroid hormone receptors. <b>2021</b> , 478, 443-461	6
138	[F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma. <b>2021</b> , 3, vdab019	1
137	Future perspectives and new directions in chemosensitizing activities to reverse drug resistance in gynecologic cancers: Emphasis on challenges and opportunities. <b>2021</b> , 339-355	1
136	Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). <b>2021</b> , 64, 909-924	5
135	Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. <b>2020</b> , 52, 1261-1269	8
134	Advances in the computational development of androgen receptor antagonists. <b>2020</b> , 25, 1453-1461	11
133	Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.	3
132	USE OF TESTOSTERONE REPLACEMENT THERAPY AFTER RADICAL PROSTATECTOMY MIGHT KILL TWO BIRDS WITH ONE STONE FROM THE PERSPECTIVE OF MEN'S HEALTH AND DISEASE CONTROL. <b>2020</b> , 16, 52	1
131	Characterization of iPS87, a prostate cancer stem cell-like cell line. <b>2020</b> , 11, 1075-1084	2
130	Cardiovascular Complications of Prostate Cancer Treatment. <b>2020</b> , 11, 555475	4
129	High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection. <b>2020</b> , 22, 323-329	21
128	Wnt/βcatenin signal transduction pathway in prostate cancer and associated drug resistance.. <b>2021</b> , 12, 40	2
127	Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized Medicine. <b>2021</b> , 38, 8-14	
126	Proteogenomic workflow reveals distinct molecular phenotypes related to breast cancer appearance	

125	Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.. <b>2021</b> , 4, 96-124	3
124	Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer. <b>2020</b> , 61, 242-249	4
123	Genetic Polymorphism and Prostate Cancer: An Update.	
122	Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer. <b>2021</b> ,	3
121	Tensor-decomposition-based unsupervised feature extraction applied to prostate cancer multiomics data.	
120	Biomarkers for Treatment Response in Advanced Prostate Cancer. <b>2021</b> , 13,	1
119	Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research. <b>2021</b> ,	0
118	Long Non-coding RNAs LINC01679 as a Competitive Endogenous RNAs Inhibits the Development and Progression of Prostate Cancer via Regulating the miR-3150a-3p/SLC17A9 Axis.. <b>2021</b> , 9, 737812	1
117	Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. <b>2021</b> , 169, 103565	5
116	Heat Shock Proteins in Benign Prostatic Hyperplasia and Prostate Cancer.. <b>2022</b> , 23,	1
115	Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells.. <b>2022</b> , 23,	0
114	Endocrine Disruptors and Prostate Cancer.. <b>2022</b> , 23,	1
113	Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.. <b>2022</b> , 13, 141	7
112	Advances in the role of heat shock protein 90 in prostate cancer.. <b>2022</b> , e14376	0
111	Integrated analysis reveals FOXA1 and Ku70/Ku80 as direct targets of ivermectin in prostate cancer.	
110	GLI3 and androgen receptor are mutually dependent for their malignancy-promoting activity in ovarian and breast cancer cells.. <b>2022</b> , 92, 110278	1
109	New TRPM8 Blockers Exert Anticancer Activity Over Castration-Resistant Prostate Cancer Models.	
108	Some Aspects of Oxidative StressInduced Prostate Cancer Therapy. <b>2022</b> , 1-21	

107	Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy.. <b>2022</b> , 14,	4
106	Computational Studies, GERS, Photovoltaic Modelling and Molecular Docking Studies of Diethylstilbestrol and Its Methyl Ether. 1-8	0
105	Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer.. <b>2022</b> , 11,	0
104	Solamargine Inhibits Prostate Cancer Cell Growth and Enhances the Therapeutic Efficacy of Docetaxel via Akt Signaling.. <b>2022</b> , 2022, 9055954	0
103	Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.. <b>2022</b> ,	0
102	Gut microbiome and prostate cancer.. <b>2022</b> ,	4
101	DETECTION OF DISEASE-CAUSING MUTATIONS IN PROSTATE CANCER BY NGS SEQUENCING.. <b>2022</b> ,	0
100	MicroRNA-like snoRNA-derived RNAs (sdRNAs) promote castration resistant prostate cancer.	0
99	Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment.. <b>2021</b> , 14,	1
98	Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer.. <b>2021</b> , 4, e2140803	0
97	Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.. <b>2021</b> , 7,	0
96	and Metastasis: Outcome of Defective DNA Repair.. <b>2021</b> , 14,	0
95	MicroRNA-like snoRNA-Derived RNAs (sdRNAs) Promote Castration-Resistant Prostate Cancer.. <b>2022</b> , 11,	0
94	Carboxyl Esterase-TRAIL Expressing Human Adipose Stem Cells Inhibit Tumor Growth in Castration-Resistant Prostate Cancer-Bearing Mice with Less Toxicity.. <b>2022</b> , 21, 15330338221093146	
93	Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression.. <b>2022</b> , 12, 854151	0
92	Spindle pole body component 25 in the androgen-induced regression of castration-resistant prostate cancer.. <b>2022</b> , 11, 519-527	1
91	New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models. <b>2022</b> , 114435	1
90	Development of novel androgen receptor antagonists based on the structure of darolutamide.. <b>2022</b> , 124, 105829	0



89	A protein coupling and molecular simulation analysis of the clinical mutants of androgen receptor revealed a higher binding for Leupaxin, to increase the prostate cancer invasion and motility.. <b>2022</b> , 146, 105537	0
88	Synthetic Small Molecules in Prostate Cancer Therapeutics. <b>2021</b> , 1-20	
87	Exercise Adherence in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <b>2022</b> , 14, 2452	0
86	Comparative Pathobiology of Canine and Human Prostate Cancer: State of the Art and Future Directions. <b>2022</b> , 14, 2727	0
85	Antitumor mechanism of combination of Angelica gigas and Torilis japonica in LNCaP prostate cancer cells via G1 arrest and inhibition of Wnt/ $\beta$ catenin and androgen receptor signaling.	0
84	Whole-exome sequencing of Indian prostate cancer reveals a novel therapeutic target: POLQ.	0
83	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <b>2022</b> , 7,	4
82	Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review. 12,	0
81	Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. <b>2022</b> , 45, 101532	1
80	Oral exposure to DEHP may stimulate prostatic hyperplasia associated with upregulation of COX-2 and L-PGDS expressions in male adult rats. <b>2022</b> ,	0
79	Current and emerging therapies for neuroendocrine prostate cancer. <b>2022</b> , 108255	0
78	Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness.	2
77	Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms. 13,	0
76	Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs. <b>2022</b> , 14, 1566	2
75	Deubiquitinases in Cancers: Aspects of Proliferation, Metastasis, and Apoptosis. <b>2022</b> , 14, 3547	2
74	Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer. <b>2022</b> , 14, 3744	2
73	New diterpenes from the marine sponge Spongionella sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein. <b>2022</b> , 12,	1
72	Androgen receptor splicing variant 7 ( ARv7 ) promotes DNA damage response in prostate cancer cells. <b>2022</b> , 36,	0

71	The determination of the relationship between p97/VCP, small VCP-interacting protein, two ERAD proteins and steroidogenesis in Leydig cell lines.	
70	Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer. <b>2022</b> , 65, 11034-11057	5
69	Protein palmitoylation in cancer: molecular functions and therapeutic potential.	0
68	De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy. 2201859	1
67	Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes. <b>2022</b> , 153, 113504	
66	Identification of the gossypol derivatives as androgen receptor inhibitor. <b>2022</b> , 75, 128952	
65	Physical exercise regulates apoptosis and prostatic inflammatory effects induced by high-fat diet in PPAR-alpha $\Delta$ mice. <b>2022</b> , 163, 106669	0
64	Current progress of nanomedicine for prostate cancer diagnosis and treatment. <b>2022</b> , 155, 113714	1
63	Synthetic Small Molecules in Prostate Cancer Therapeutics. <b>2022</b> , 985-1004	0
62	Some Aspects of Oxidative StressInduced Prostate Cancer Therapy. <b>2022</b> , 3307-3327	0
61	Molecular Modeling Studies of Natural Inhibitors of Androgen Signaling in Prostate Cancer. <b>2022</b> , 21, 117693512211185	1
60	Molecular mechanism of action of estrogens, progestins, and androgens. <b>2023</b> , 123-159	0
59	Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer.	0
58	Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.	0
57	Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. <b>2022</b> , 13,	0
56	Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors. <b>2022</b> , 11, 2785	0
55	Drivers of Radioresistance in Prostate Cancer. <b>2022</b> , 11, 5637	1
54	Review of in silico studies dedicated to the nuclear receptor family: Therapeutic prospects and toxicological concerns. 13,	1

53	Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1H-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.	0
52	Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. <b>2022</b> ,	2
51	Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones. <b>2022</b> , 13,	0
50	A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients. 13,	0
49	The Mechanistic Roles of Sirtuins in Breast and Prostate Cancer. <b>2022</b> , 14, 5118	1
48	Repression of SLC22A3 by the AR-V7 / YAP1 / TAZ axis in enzalutamide-resistant castration-resistant prostate cancer.	0
47	Risk Allele Frequency Analysis and Risk Prediction of Single-Nucleotide Polymorphisms for Prostate Cancer. <b>2022</b> , 13, 2039	1
46	Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network.	0
45	Cardiometabolic side effects of androgen deprivation therapy in prostate cancer. <b>2022</b> , 16, 216-222	0
44	Differentially expressed AC077690.1, AL049874.3 and AP001037.1 lncRNAs in prostate cancer. <b>2022</b> , 74, 359-366	0
43	1-Benzoyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells. <b>2023</b> , 246, 114982	0
42	Synthesis and evaluation of 7-(3-aminopropoxy)-substituted flavone analogue as a topoisomerase II $\alpha$ catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells. <b>2023</b> , 246, 114999	0
41	Sex steroid hormones and DNA repair regulation: Implications on cancer treatment responses. <b>2023</b> , 227, 106230	0
40	PROTAC: targeted drug strategy. Principles and limitations. <b>2022</b> , 71, 2310-2334	0
39	Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. <b>2022</b> , 8,	0
38	Intermittent Use of Anti-Hormonal Agents for the Endocrine Therapy of Sex-Hormone-Dependent Breast and Prostate Cancer: A Protocol for a Systematic Review. <b>2022</b> , 19, 15486	0
37	Transglutaminase-2 regulates mucin-1 expression and androgen independency in prostate cancer cell lines via an alternative truncated isoform.	0
36	Chemopreventive effect of cinnamon and its bioactive compounds in a rat model of premalignant prostate carcinogenesis.	0

- 35 Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?. **2022**, 14, 6071 ○
- 34 Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries. **2023**, 24, 1435 ○
- 33 Male sex hormones, aging, and inflammation. **2023**, 24, 1-25 ○
- 32 Compressed Prostate Cancer Cells Decrease Osteoclast Activity While Enhancing Osteoblast Activity In Vitro. **2023**, 24, 759 ○
- 31 Clostridium difficile Infection Is Associated With Decreased Prostate Cancer Risk: A Retrospective Cohort Study. **2023**, ○
- 30 Transcription Factors and Cancer. **2023**, 29, 38-46 ○
- 29 Novel Insights into the Role of the Antioxidants in Prostate Pathology. **2023**, 12, 289 1
- 28 Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. 41, ○
- 27 Galaxolide and Irgacure 369 are novel environmental androgens. **2023**, 324, 138329 ○
- 26 An integrated in vitro/in silico approach to assess the anti-androgenic potency of isobavachin. **2023**, 176, 113764 ○
- 25 Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. **2022**, 30, 137-155 ○
- 24 Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. **2023**, 24, 2939 ○
- 23 The correlation between the expression of ubiquitin-conjugating enzyme 2C and prostate cancer prognosis. ○
- 22 Cheminformatic Analysis and Machine Learning Modeling to Investigate Androgen Receptor Antagonists to Combat Prostate Cancer. **2023**, 8, 6729-6742 ○
- 21 Toxic Masculinity—What Is Known about the Role of Androgen Receptors in Head and Neck Squamous Cell Carcinoma. **2023**, 24, 3766 ○
- 20 Ubiquitin specific peptidases and prostate cancer. 11, e14799 1
- 19 The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome. **2023**, 15, 1375 ○
- 18 Metabolism-Guided Selective Androgen Receptor Antagonists: Design, Synthesis, and Biological Evaluation for Activity against Enzalutamide-Resistant Prostate Cancer. **2023**, 66, 3372-3392 ○

- 17 Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients. 13,
- 16 Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer. **2023**, 38, 100890
- 15 Circular RNAs in eukaryotic cells: origin, characteristics, mechanisms of molecular functioning in human malignant diseases. **2023**, 20, 335-384
- 14 LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF- $\kappa$ B and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects. **2023**, 24, 5082
- 13 State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer. 13,
- 12 Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. **2023**, 8,
- 11 Prostate Cancer: Advances in Genetic Testing and Clinical Implications. **2023**, 3, 91-103
- 10 ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis. **2023**, 23,
- 9 The effect of encomir-93 mimic transfection on the expression of miR-93 and PSA and androgen receptor in prostate cancer LNCap cell line. **2022**,
- 8 Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis. **2023**, 17, 155798832311651
- 7 Study of Glabranin as an Inhibitor Against Prostate Cancer: Molecular Docking, Molecular Dynamics Simulation, MM-PBSA Calculation and QSAR Prediction.
- 6 Comparative oncology: overcoming human cancer through companion animal studies.
- 5  $\beta$ Mangostin Promotes In Vitro and In Vivo Degradation of Androgen Receptor and AR-V7 Splice Variant in Prostate Cancer Cells. **2023**, 15, 2118
- 4 Rewiring of miRNA-mRNA bipartite co-expression network as a novel way to understand the prostate cancer related players. 1-12
- 3 Long noncoding RNA GHET1 promotes cell proliferation through oxidative stress in prostate cancer.
- 2 Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer.
- 1 Use of PARP inhibitors in prostate cancer: from specific to broader application. 14,